Propanc Biopharma, a Nasdaq-listed biotech firm, has secured up to $100 million to bolster its digital asset strategy.
Related Posts
Polygon NFT sales surpass Ethereum, driven by RWA-based Courtyard
Ethereum lost its spot as the top NFT platform from the first time, to its layer 2 Polygon.
Industry must look past the arbitrary buying and selling of pixels | Opinion
The floor price of popular non-fungible tokens (NFTs) is plummeting. Across the board, we see stories of vast…
Bitcoin (BTC) battles macro headwinds despite improved ETF inflows
Bitcoin price remains range-bound amid long-term holder selling and falling demand. US Bitcoin ETFs inflows signal cautious institutional…